CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Adaptive Study of Local Ablative Therapy (LAT) for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Using Minimal Residual Disease (MRD) as an Integral Biomarker

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05429320
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:31.629567+00:00
Published At: 2026-02-02T00:00:00+00:00
Record Updated At: 2026-02-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-small Cell Lung Cancer", "Metastatic Non Small Cell Lung Cancer", "Nsclc", "NSCLC Stage IV", "Minimal Residual Disease", "Non Small Cell Lung Cancer Metastatic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-02"
protocolSection.identificationModule.nctId: "NCT05429320"
protocolSection.identificationModule.officialTitle: "A Phase II Adaptive Study of Local Ablative Therapy (LAT) for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Using Minimal Residual Disease (MRD) as an Integral Biomarker"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.